Aroa Biosurgery Ltd (ARX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aroa Biosurgery Ltd (ARX) has a cash flow conversion efficiency ratio of 0.045x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$3.64 Million ≈ $2.58 Million USD) by net assets (AU$80.93 Million ≈ $57.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ARX stock market capitalisation for the company's overall valuation and market capitalisation.
Aroa Biosurgery Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Aroa Biosurgery Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aroa Biosurgery Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aroa Biosurgery Ltd ranked by their cash flow conversion efficiency. Explore how high is Aroa Biosurgery Ltd's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harbour Link Group Bhd
KLSE:2062
|
0.023x |
|
Siam Pan Group PCL
BK:SPG
|
0.014x |
|
Agora S.A.
WAR:AGO
|
0.079x |
|
Jay Bharat Maruti Limited
NSE:JAYBARMARU
|
0.044x |
|
Humacyte Inc
NASDAQ:HUMA
|
-8.403x |
|
La Française de l'Energie S.A.
PA:FDE
|
0.040x |
|
First Guaranty Bancshares, Inc.
NASDAQ:FGBI
|
-0.003x |
|
Annehem Fastigheter AB
ST:ANNE-B
|
0.012x |
Annual Cash Flow Conversion Efficiency for Aroa Biosurgery Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Aroa Biosurgery Ltd from 2014 to 2025. View Aroa Biosurgery Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | AU$84.59 Million ≈ $59.85 Million |
AU$-2.33 Million ≈ $-1.65 Million |
-0.028x | +64.51% |
| 2024-03-31 | AU$87.09 Million ≈ $61.62 Million |
AU$-6.76 Million ≈ $-4.79 Million |
-0.078x | -109.81% |
| 2023-03-31 | AU$95.38 Million ≈ $67.49 Million |
AU$-3.53 Million ≈ $-2.50 Million |
-0.037x | +67.71% |
| 2022-03-31 | AU$93.40 Million ≈ $66.09 Million |
AU$-10.71 Million ≈ $-7.58 Million |
-0.115x | -22.95% |
| 2021-03-31 | AU$53.69 Million ≈ $37.99 Million |
AU$-5.01 Million ≈ $-3.54 Million |
-0.093x | -471.64% |
| 2020-03-31 | AU$62.86 Million ≈ $44.48 Million |
AU$1.58 Million ≈ $1.12 Million |
0.025x | +4523.65% |
| 2019-03-31 | AU$11.52 Million ≈ $8.15 Million |
AU$-6.54K ≈ $-4.62K |
-0.001x | +99.96% |
| 2018-03-31 | AU$1.77 Million ≈ $1.25 Million |
AU$-2.80 Million ≈ $-1.98 Million |
-1.586x | -1251.70% |
| 2017-03-31 | AU$6.28 Million ≈ $4.44 Million |
AU$-737.06K ≈ $-521.52K |
-0.117x | -70.03% |
| 2016-03-31 | AU$5.91 Million ≈ $4.18 Million |
AU$-408.04K ≈ $-288.71K |
-0.069x | +64.65% |
| 2015-03-31 | AU$6.92 Million ≈ $4.90 Million |
AU$-1.35 Million ≈ $-956.64K |
-0.195x | -8.88% |
| 2014-03-31 | AU$7.58 Million ≈ $5.36 Million |
AU$-1.36 Million ≈ $-961.75K |
-0.179x | -- |
About Aroa Biosurgery Ltd
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and co… Read more